Mid-Atlantic Bio

Mid-Atlantic BioTherapeutics (MABT) is a clinical-stage biotechnology company dedicated to developing transformative therapies for life-threatening infectious diseases and neurodegenerative disorders. Founded in 2011 and based in Doylestown, Pennsylvania, the company leverages its proprietary IMT504 immunotherapy platform, a non-CpG oligonucleotide, to address unmet medical needs in conditions such as rabies and Alzheimer's disease. MABT's lead candidate, IMT504, has received Orphan Drug Designation for rabies and is advancing toward pivotal clinical trials. The company has expanded its portfolio through the acquisition of XPose Therapeutics, adding a pipeline of small molecule inhibitors targeting "undruggable" DNA Damage Response (DDR) proteins for oncology, and collaborates with Accelero Biostructures on novel USP30 inhibitors for Parkinson's disease.